BSE filing, NSE: CMMHOSP. Summary written from the filing by ALFA Finder's alert engine.
Chennai Meenakshi Multispeciality Hospital Ltd: key numbers
- Share price
- ₹38.00
- Market cap
- ₹28.38 Cr
- Revenue (annual)
- ₹37.04 Cr
- Net profit (annual)
- ₹-1.12 Cr
- P/E (TTM)
- -33.2×Sector 53.8×
- Promoter holding
- 57.10%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chennai Meenakshi Multispeciality Hospital Ltd
All →Chennai Meenakshi Multispeciality Hospital Q2 FY27 Results: Net Loss of ₹0.3 Cr
Chennai Meenakshi Multispeciality Hospital Ltd reported revenue from operations of ₹8.6 Cr (-9.5% YoY) and a net loss of ₹0.3 Cr for Q2 FY27.
- Key figure
- Net loss ₹0.3 Cr
Chennai Meenakshi Multispeciality Hospital Other Announcement
Chennai Meenakshi Multispeciality Hospital's quarterly shareholding pattern shows promoters holding 57.10%. The routine filing reports no corporate action or event value.
Chennai Meenakshi Multispeciality Hospital Board Meeting Date
Chennai Meenakshi Multispeciality Hospital will hold a board meeting on 2 November 2026 to consider quarterly and half-year unaudited results. Trading window remains closed from 1 October until 48 hours after results.
Chennai Meenakshi Multispeciality Hospital Other Announcement
Quarterly shareholding pattern for the period ended September 30, 2026, filed in compliance with SEBI Regulation 31(1)(b).
Chennai Meenakshi Multispeciality Hospital Board Meeting Outcome
Chennai Meenakshi Multispeciality Hospital Limited has reconstituted its Audit Committee and Stakeholders Relationship Committee following the recent cessation of certain directors from the Board.
Chennai Meenakshi Multispeciality Hospital Annual General Meeting
Chennai Meenakshi Multispeciality Hospital conducted its 36th Annual General Meeting on September 30, 2026, transacting ordinary and special business items via remote e-voting and AGM voting.
Other legal & regulatory announcements
All →Corona Remedies Legal & Regulatory
Corona Remedies received an NPPA demand notice of Rs 4.88 Crore for alleged DPCO 2013 price violations. The company is evaluating it and reports no material financial impact.
- Value
- ₹4.88 Cr
Easy Trip Planners Legal & Regulatory
Easy Trip Planners received a GST show-cause notice proposing a penalty of about Rs 67.41 Crore. The company expects no immediate financial impact and will contest it.
- Value
- ₹67.41 Cr
Ruparel Food Products Legal & Regulatory
Ruparel Food Products paid a Rs 2,360 BSE fine for a late Regulation 34 annual report. The company says Regulation 43A does not apply to it.
- Value
- ₹0.00 Cr
Integra Switchgear Legal & Regulatory
Integra Switchgear received a SEBI adjudication order levying penalties of ₹13 lakh. The erstwhile promoters have undertaken to bear any resulting liability.
- Value
- ₹0.13 Cr
- From
- Securities and Exchange Board of India (SEBI)
Airfloa Rail Technology Legal & Regulatory
Airfloa Rail received a Madras High Court interim stay on CSR penalties under Section 135(7). Conditional relief requires paying 50% of the ROC penalty within twelve weeks.
- Value
- ₹1.05 Cr
Timken India Legal & Regulatory
Timken India's GST appeal was rejected, upholding a Rs 8.19 Crore demand plus interest and penalty. The company plans to appeal and expects no immediate financial impact.
- Value
- ₹8.19 Cr